BioWorld

Feb. 7, 2011

View Archived Issues

The Dark Side of Demand: Scaling Up Biologics

Increased demand for a drug is a welcome outcome of gaining regulatory approval and successful marketing. But scaling up production of biologics isn't easy. Read More

Money Raised Year to Date

Read More

Antitrust Probe for Alexion? History Shows No Big Deal

Read More

Obesity Drug Strike-Out May Shift Focus Back to GLP-1s

Read More

Week in Review

Read More

Word on the Street

Read More

U.S. Public Offering Performance By Underwriter: Jan. 1 - Dec. 31, 2010

Read More

Underwriters' Performance on IPOs: Jan. 1 - Dec. 31, 2010

Read More

Lead Underwriter Performance on All U.S. Offerings: Jan. 1 - Dec. 31, 2010

Read More

Stock Gainers and Losers For The Week

Read More

BioWorld Stock Report For Public Biotechnology Companies

Read More